Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information. |
|
Device | BRACAnalysis CDx |
Applicant | MYRIAD GENETIC LABORATORIES 320 Wakara Way Salt Lake City, UT 84108 |
PMA Number | P140020 |
Supplement Number | S027 |
Date Received | 01/27/2023 |
Decision Date | 04/26/2023 |
Advisory Committee |
Pathology |
Clinical Trials | NCT01847274
|
Supplement Type | Normal 180 Day Track |
Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
Expedited Review Granted? | No |
Combination Product | No |
Approval Order Statement Approval for the change of Zejula® (niraparib) indication from a complementary diagnostic to a companion diagnostic to aid in identifying ovarian cancer patients with deleterious or suspected deleterious germline BRCA1 and BRCA2 mutations, who are or may become eligible for maintenance treatment with Zejula® (niraparib). |
|
|